Literature DB >> 25768833

Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma.

Matthew Z Sun1, Taemin Oh, Michael E Ivan, Aaron J Clark, Michael Safaee, Eli T Sayegh, Gurvinder Kaur, Andrew T Parsa, Orin Bloch.   

Abstract

OBJECT There are few and conflicting reports on the effects of delayed initiation of chemoradiotherapy on the survival of patients with glioblastoma. The standard of care for newly diagnosed glioblastoma is concurrent radiotherapy and temozolomide chemotherapy after maximal safe resection; however, the optimal timing of such therapy is poorly defined. Given the lack of consensus in the literature, the authors performed a retrospective analysis of The Cancer Genome Atlas (TCGA) database to investigate the effect of time from surgery to initiation of therapy on survival in newly diagnosed glioblastoma. METHODS Patients with primary glioblastoma diagnosed since 2005 and treated according to the standard of care were identified from TCGA database. Kaplan-Meier and multivariate Cox regression analyses were used to compare overall survival (OS) and progression-free survival (PFS) between groups stratified by postoperative delay to initiation of radiation treatment. RESULTS There were 218 patients with newly diagnosed glioblastoma with known time to initiation of radiotherapy identified in the database. The median duration until therapy was 27 days. Delay to radiotherapy longer than the median was not associated with worse PFS (HR = 0.918, p = 0.680) or OS (HR = 1.135, p = 0.595) in multivariate analysis when controlling for age, sex, KPS score, and adjuvant chemotherapy. Patients in the highest and lowest quartiles for delay to therapy (≤ 20 days vs ≥ 36 days) did not statistically differ in PFS (p = 0.667) or OS (p = 0.124). The small subset of patients with particularly long delays (> 42 days) demonstrated worse OS (HR = 1.835, p = 0.019), but not PFS (p = 0.74). CONCLUSIONS Modest delay in initiation of postoperative chemotherapy and radiation does not appear to be associated with worse PFS or OS in patients with newly diagnosed glioblastoma, while significant delay longer than 6 weeks may be associated with worse OS.

Entities:  

Keywords:  CI = confidence interval; HR = hazard ratio; KPS = Karnofsky Performance Scale; OS = overall survival; PFS = progression-free survival; TCGA = The Cancer Genome Atlas; The Cancer Genome Atlas; glioblastoma; oncology; overall survival; progression-free survival; treatment delay

Mesh:

Year:  2015        PMID: 25768833     DOI: 10.3171/2014.9.JNS14193

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  27 in total

1.  Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study.

Authors:  Haihui Jiang; Wei Zeng; Xiaohui Ren; Yong Cui; Mingxiao Li; Kaiyuan Yang; Mohammad Elbaroody; Song Lin
Journal:  J Neurooncol       Date:  2019-06-07       Impact factor: 4.130

2.  Early imaging marker of progressing glioblastoma: a window of opportunity.

Authors:  Na Tosha N Gatson; Shane P Bross; Yazmin Odia; Gino J Mongelluzzo; Yirui Hu; Laura Lockard; Jesse J Manikowski; Anand Mahadevan; Syed A J Kazmi; Michel Lacroix; Andrew R Conger; Joseph Vadakara; Lakshmi Nayak; T Linda Chi; Minesh P Mehta; Vinay K Puduvalli
Journal:  J Neurooncol       Date:  2020-06-29       Impact factor: 4.130

3.  Early initiation of chemoradiation following index craniotomy is associated with decreased survival in high-grade glioma.

Authors:  Jay K Nathan; Amanda L Brezzell; Michelle M Kim; Denise Leung; D Andrew Wilkinson; Shawn L Hervey-Jumper
Journal:  J Neurooncol       Date:  2017-07-25       Impact factor: 4.130

4.  Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy.

Authors:  Chan Woo Wee; Eunji Kim; Tae Min Kim; Chul-Kee Park; Jin Wook Kim; Seung Hong Choi; Roh-Eul Yoo; Soon-Tae Lee; Il Han Kim
Journal:  J Neurooncol       Date:  2017-05-25       Impact factor: 4.130

5.  The impact of the time to start radiation therapy on overall survival in newly diagnosed glioblastoma.

Authors:  Vanessa Montes Santos; Gustavo Nader Marta; Marcella Coelho Mesquita; Rossana Veronica Mendoza Lopez; Edla Renata Cavalcante; Olavo Feher
Journal:  J Neurooncol       Date:  2019-03-08       Impact factor: 4.130

6.  Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database.

Authors:  Deborah T Blumenthal; Minhee Won; Minesh P Mehta; Mark R Gilbert; Paul D Brown; Felix Bokstein; David G Brachman; Maria Werner-Wasik; Grant K Hunter; Egils Valeinis; Kirsten Hopkins; Luis Souhami; Steven P Howard; Frank S Lieberman; Dennis C Shrieve; Merideth M Wendland; Cliff G Robinson; Peixin Zhang; Benjamin W Corn
Journal:  Neuro Oncol       Date:  2018-06-18       Impact factor: 12.300

7.  Early tumor growth between initial resection and radiotherapy of glioblastoma: incidence and impact on clinical outcomes.

Authors:  Javier E Villanueva-Meyer; Seunggu J Han; Soonmee Cha; Nicholas A Butowski
Journal:  J Neurooncol       Date:  2017-05-31       Impact factor: 4.130

8.  Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.

Authors:  Alexandra McAleenan; Claire Kelly; Francesca Spiga; Ashleigh Kernohan; Hung-Yuan Cheng; Sarah Dawson; Lena Schmidt; Tomos Robinson; Sebastian Brandner; Claire L Faulkner; Christopher Wragg; Sarah Jefferies; Amy Howell; Luke Vale; Julian P T Higgins; Kathreena M Kurian
Journal:  Cochrane Database Syst Rev       Date:  2021-03-12

9.  Residual enhancing disease after surgery for glioblastoma: evaluation of practice in the United Kingdom.

Authors:  Ruichong Ma; Aswin Chari; Paul M Brennan; Andrew Alalade; Ian Anderson; Anna Solth; Hani J Marcus; Colin Watts
Journal:  Neurooncol Pract       Date:  2017-09-27

10.  Heterogeneity of radiation response in mesenchymal subtype glioblastoma: molecular profiling and reactive oxygen species generation.

Authors:  Christopher P Cifarelli; Angelica Jacques; Andrey Bobko
Journal:  J Neurooncol       Date:  2021-02-10       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.